Serum testosterone level and overall survival in first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer patients.

Maysa Tamara Silveira Vilbert,Marcelle Goldner Cesca,Natasha Carvalho Pandolfi,Vinícius Fernando Calsavara,Bruno Cezar de Mendonça Uchôa,Poliana de Andrade,Ricardo Lima Coelho,Marcelo Corassa,Jose Augusto Rinck,Aldo A. Dettino,Thiago Bueno Oliveira

Serum testosterone level and overall survival in first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer patients.

2020

Maysa Tamara Silveira Vilbert
Marcelle Goldner Cesca
Natasha Carvalho Pandolfi
Vinícius Fernando Calsavara
Bruno Cezar de Mendonça Uchôa
Poliana de Andrade
Ricardo Lima Coelho
Marcelo Corassa
Jose Augusto Rinck
Aldo A. Dettino
Thiago Bueno Oliveira

e17545Background: Androgen receptor-targeted agents Abiraterone and Enzalutamide (Abi/Ez) prolonged overall survival in metastatic castration resistant prostate cancer (mCRPC). Patients with very-l...

Keywords:

Enzalutamide
Abiraterone
Oncology
overall survival
Pathology
Serum testosterone level
castration resistant
Internal medicine
first line
Prostate cancer
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations